Dementia professor on new Biogen approval: The first small step towards new developments
Biogen's Aduhelm is the first new Alzheimer's drug approved for nearly twenty years, and this pleases Professor of Clinical Neurology Gunhild Waldemar.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The official approval of a drug rarely resonates outside the circle of medical professionals and patients who stand to benefit from the new treatment. However, US biotech company Biogen has garnered attention due to its new drug, which was approved on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bogus drugs and medical equipment abound in Europe
For subscribers
Eli Lilly lowers guidance for 2021
For subscribers
